– USA, CT – Perosphere Technologies Inc., a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced the appointment of Michelle Brennan to its Board of Directors.
About Michelle Brennan
Michelle Brennan brings over three decades of demonstrated leadership in healthcare, including expertise in regulatory affairs, clinical trials, market access, and global commercialization directly related to medical devices.
“I am honored to have been invited to join Perosphere’s Board of Directors, as we share a deeply felt commitment to saving lives, time, and money while elevating the standard of patient care,” said Michelle Brennan. “Throughout my career, I have sought to drive progress that improves treatment, and the work that Perosphere is doing mirrors that commitment.”
As former Company Group Chair of Medical Devices at Johnson & Johnson, she was instrumental in driving initiatives that prioritize patient safety, comfort, and well-being while growing the division. Brennan is also the former President, of Enterprise Standards & Productivity at Johnson & Johnson, where she sought to optimize systems, processes, and business models. Before that role, she served as Worldwide President for Ethicon Energy, also at Johnson & Johnson, where she installed a strategic leadership team to discover innovative opportunities and shape product development.
Michelle Brennan is currently on the Board of Directors of Cardinal Healthcare, a leading medical supplier in the US, and Masimo, a medical device company, and previously served on the board of COUPA Software until their recent acquisition. She is based in Spearfish, South Dakota.
About Perosphere Technologies
Perosphere Technologies is changing the way decisions are made for patients at risk of bleeding. A private medical technologies company, Perosphere is focused on the development and commercialization of its novel PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including DOACs. The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The PoC Coagulometer has a CE Mark in the EU but is not yet cleared in the US.
For more information: https://perospheretech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
